Bausch Health Companies Inc.
HealthcareNYSE:BHC · New York Stock Exchange
-$0.10 today
Vol 1.56M · Avg 1.70M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.9%
avg 45.1%
ROIC
3.2%
avg 0.1%
ROA
0.6%
avg -2.5%
Analysis
ROIC is currently the strongest return metric at 3.2% versus its period average of 0.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas J. Appio | Chief Executive Officer & Director | $3.84M | — | 64 | $3.45M | 0.92% |
Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer | $1.39M | — | 61 | $706,478.00 | 0.19% |
Seana Carson | Executive Vice President & General Counsel | $1.33M | — | 53 | $616,761.00 | 0.17% |
Aimee J. Lenar | Executive Vice President of US Pharma | $1.31M | — | 50 | $400,335.00 | 0.11% |
Cees Heiman | Senior Vice President of Europe & Canada | — | — | — | — | — |
Garen Sarafian | Vice President & Head of Investor Relations | — | — | — | — | — |
Jiny Kim | Senior Vice President of Solta Medical | — | — | 48 | — | — |
Kathleen Fitzpatrick | Executive Vice President and Chief HR & Communications Officer | — | — | — | — | — |
Mirza Dautbegovic | Executive Vice President & Chief Operating Officer | — | — | — | — | — |
Steven Lee | Senior Vice President, Controller & Chief Accounting Officer | — | — | 55 | $95,210.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$370.55M
Sells
6
$467,456.38
Net Sentiment
+$370.09M
Net buying
Most Active
Paulson John
5 transactions
1–10 of 12
Analysis
Insiders reported 6 buys worth $370.55M and 6 sells worth $467,456.38 over the last 12 months. That adds up to net buying of $370.09M. Paulson John was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +44.2% | -0.7% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | +167.6% | +1.3% (15yr)1 analysts |
Analysis
Recent growth has been strongest in EBIT at +167.6% over three years. Forward estimates point to EBIT at +1.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.60B
Haemonetics Corporation
NYSE:HAE
$3.55B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.02B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.91B
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
$1.86B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Perrigo Company plc
NYSE:PRGO
$1.52B
Alvotech
NASDAQ:ALVO
$1.30B
Who manages BHC?
Bausch Health Companies Inc. (BHC) lists 10 active executives. The top listed executive is Thomas J. Appio, Chief Executive Officer & Director.
Are BHC insiders buying or selling?
Recent insider activity shows net buying of $371.58M.
Explore More
Continue the stock analysis
Jump to another research area for this company.